Janux Therapeutics Inc (JANX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
29.94 -0.49 (-1.61%) 03/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 29.94 unch (unch) 16:55 ET
for Fri, Mar 21st, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Cash Flows From Operating Activities | |||||
Net Income | -68,994 | -58,293 | -63,059 | -32,672 | -6,784 |
Depreciation Amortization | -8,525 | -5,733 | -1,342 | -59 | 13 |
Accounts receivable | N/A | N/A | N/A | 8,000 | -8,000 |
Accounts payable and accrued liabilities | 1,584 | 277 | -294 | 2,139 | 14 |
Other Working Capital | 685 | -6,554 | 4,276 | 8,842 | 389 |
Other Operating Activity | 31,436 | 19,728 | 17,497 | -3,226 | 9,999 |
Operating Cash Flow | $-43,814 | $-50,575 | $-42,922 | $-16,976 | $-4,369 |
Cash Flows From Investing Activities | |||||
Change In Deposits | -257,662 | -39,344 | 64,711 | -339,481 | N/A |
PPE Investments | -359 | -1,850 | -6,445 | -1,482 | N/A |
Investing Cash Flow | $-258,021 | $-41,194 | $58,266 | $-340,963 | $N/A |
Cash Flows From Financing Activities | |||||
Change In Short Term Borrowing | N/A | N/A | N/A | N/A | 2,500 |
Common Stock Issued | 713,235 | 59,548 | 500 | 1,810 | 70 |
Other Financing Activity | 0 | 0 | 0 | 384,714 | 8,954 |
Financing Cash Flow | $713,235 | $59,548 | $500 | $386,524 | $11,524 |
Beginning Cash Position | 20,021 | 52,242 | 36,398 | 7,813 | 658 |
End Cash Position | 431,421 | 20,021 | 52,242 | 36,398 | 7,813 |
Net Cash Flow | $411,400 | $-32,221 | $15,844 | $28,585 | $7,155 |
Free Cash Flow | |||||
Operating Cash Flow | -43,814 | -50,575 | -42,922 | -16,976 | -4,369 |
Capital Expenditure | -359 | -1,850 | -6,445 | -1,482 | N/A |
Free Cash Flow | -44,173 | -52,425 | -49,367 | -18,458 | -4,369 |